The lung resistance-related protein (LRP) plays an important role in chemoresistance of tumor cells probably by altering nuclear-cytoplasmic transport processes. We analyzed the association between LRP expression and hepatocarcinogenesis in humans and rats by RT-PCR, immunoblotting and immunohistochemistry. LRP was found in hepatocytes and bile epithelia of normal human and rat liver showing distinct interindividual variations. In human tissues, the LRP expression levels of dysplastic liver nodules, hepatocellular adenomas and carcinomas were highly variable including decreased but also distinctly increased staining intensities. The mean expression levels, however, were comparable to the surrounding. Considerable levels of LRP mRNA and protein were also found in human hepatoma cell lines. To study LRP expression from the beginning of hepatocarcinogenesis onwards, rats were subjected to a tumor initiation/promotion protocol leading to preneoplastic hepatocytes present as single cells or multicellular clones, followed by adenoma and carcinoma. All of the (pre)neoplastic rat liver lesions expressed, comparable to the surrounding tissue, considerable amounts of LRP. We conclude, that LRP might be one mechanism involved in the intrinsically high but variable chemoresistance of normal and (pre)neoplastic hepatocytes.
Introduction
Liver cancer is among the seven leading causes of cancer death worldwide. Prognosis is usually poor and no effective chemotherapeutic treatment is currently available (4, 15) . One explanation may be that the major function of the liver is to process and detoxify numerous structurally diverse compounds (40) . Drug metabolites are extruded from the hepatocytes by specific membrane proteins, like the multispecific organic anion transporters (MOAT) which comprise members of the multidrug resistance protein family (MRP), the bile acid transporter, ionmotive ATPases and P -glycoprotein (21, 25) . These transporters contribute to the broad chemoresistance of hepatocytes, known as intrinsic multidrug resistance (MDR). The liver, like several other tissues, preserves protection mechanisms during malignant progression resulting in intrinsically drug-resistant tumors (12).
Additionally to a protective function, MDR might also play a role in hepatocarcinogenesis.
(Pre)malignant hepatocytes have been shown to acquire additional resistance to cytotoxic agents by activation of P-glycoprotein and phase-II detoxifying enzymes, including the placentar glutathione-S-transferase (GSTp) (10, 30, 35, 38) . This might provide a selection advantage to the (pre)neoplastic hepatocytes in a toxic environment and thus drive the further development to malignant tumors (11, 32, 35, 37, 41) .
A newly identified protein, called lung resistance protein (LRP) due to its discovery in a drug-resistant lung cancer cell line, has been associated with cellular chemoresistance (36) . LRPalso known as major vault protein -is the main structural component of vaults, the largest ribonucleoprotein particles known so far. Besides multiple copies of LRP (100 kDa), the vault complex is composed of two proteins (p240 and p193) and an untranslated RNA (vRNA) molecule.
The two larger protein components were identified as telomerase-associated protein TEP1 and as a new poly-ADP-ribose-polymerase (vault PARP) (22, 23) . Vaults have been detected originally in preparations of coated vesicles from rat liver (20) . The importance of LRP in detoxification processes is substantiated by the fact that it is highly expressed in epithelia potentially exposed to toxins (17) . Others and we have shown a distinct correlation of LRP expression with chemoresistance against diverse antineoplastic drugs including platinum agents in various cancer cell lines derived from lung cancer, gliomas and other tumors (36, 2, 3) . Furthermore, a distinct LRP expression was found also in highly chemoresistant soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors (33) . In several malignancies, LRP expression has predictive value for poor response to chemotherapy (36) . LRP induction in colon cancer cells by sodium butyrate reduced nuclear accumulation of the anti-cancer drug doxorubicin (24) . These results corroborate the hypothesis that vaults are involved in nucleo-cytoplasmatic transport (7).
The possible role of LRP for i ntrinsic or acquired MDR of hepatocytes and their (pre)malignant counterparts has not been extensively investigated so far. Two studies gave conflicting results about the expression and possible function of LRP in normal hepatocytes (17, 39) .
We therefore studied the extent of LRP expression in human and rat hepatocarcinogenesis. In both species we observed considerable levels of LRP in unaltered liver and all steps of liver (pre)neoplasia. Thus LRP respectively vaults might be one factor contributing to the high intrinsic chemoresistance of liver tumor.
Materials and Methods

Animals and Treatment.
Male SPF Wistar rats, 3 weeks old, were obtained from the Forschungsinstitut für Versuchstierzucht und Versuchstierhaltung (Himberg, Austria). Animals were kept under standardized conditions and were treated as described (26) . Briefly, N-nitrosomorpholine (NNM, Sigma, St. Louis, USA), dissolved in PBS (pH 7.4), was given as a single dose of 250mg NNM/10ml solution/kg body weight by gavage. After a recovery period of 4 days animals were treated with phenobarbital (PB, Fluka AG, Buchs, Switzerland), which was admixed to the diet (Altromin 1321N, Altromin, Lage, Germany) at a daily dose of 50mg/kg body weight. Controls received basal diet ad libitum. Animals were killed by decapitation under CO 2 -asphyxia. Time points of sacrifice were 91 and 266 days post NNM treatment. For details see (26) . The experiment was performed according to Austrian guidelines for animal care and protection.
Human Liver Samples.
Patients suffering from cirrhosis (n=13) or cholangiocellular carcinoma (n=2) were subjected to liver transplantation. Patients with dysplastic liver nodules (n = 13), hepatocellular adenoma (n = 5) or carcinoma (n = 20) underwent liver surgery. Chemotherapy had not been applied before surgery. Causative factors for the development of the lesions and diagnoses see Table 1 . The classification of the benign and malignant liver lesions followed the International Working Party (16) as well as Edmondson and Steiner (9), respectively. Tissue samples were immediately fixed in 10% buffered formaldehyde; additional samples were stored in liquid nitrogen.
Cell Culture.
The human hepatoma cell lines HepG2 (ATCC-No HB-8065), Hep2B2.1-7 (HB-8064), Chang liver (CCl-13) and WRL 68 (CL-48), obtained from the American Type Culture Collection (Rockville, MD, USA), were maintained in vitro as described (13). The small-cell lung cancer cell line GLC-4 and its drug-resistant LRP-overexpressing subline GLC-4/ADR (42) were a gift of Dr. E.G.E. de Vries, University of Groningen, The Netherlands.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
RNA was extracted from cell-lines and RT-PCR was performed as described previously (3).
Two oligonucleotide primer sets were used: set I resulted in the amplification of a 284 bp PCR product specific for human LRP (Genbank accession number X79882); primer set II specific for GAPDH (358bp) was used as a housekeeping gene (3) . Amplification products were separated by acrylamide gel electrophoresis and were stained with ethidium bromide. Dynamics of PCR amplification, as measured by ethidium bromide staining, was evaluated for both genes and revealed an optimum of 20 cycles for GAPDH and 28 cycles for LRP.
Immunoblotting
Tissue samples or hepatoma cells were suspended in lysis puffer (50mM Tris, 300mM NaCl, 0.5% Triton X at pH 7.6, containing several protease inhibitors and PMSF) for 10min at 4°C, frozen and thawed three times and centrifuged at 5000rpm for 15 min at 4°C. Supernatant was separated by SDS-PAGE and transferred and detected and quantified using the Gel-Doc System from Bio-Rad (Munich, Germany) as described (3) . Primary antibodies (anti-LRP mouse monoclonal antibody, Transduction Laboratories, Lexington, KY; anti-beta-actin , clone AC-15 from Sigma) were applied at a working dilution of 1:1000.
Histology
Specimens of human liver, fixed in 4% buffered formaldehyde and rat liver tissue, fixed in Carnoy´s solution, were processed as described (14). Serial sections were cut and stained with hematoxylin & eosin and for LRP. For rat samples an additional section was stained for placental glutathione-S-transferase (GSTp).
Immunostaining for LRP and GSTp.
Primary antisera: mouse (LRP-56) or rat (LMR5) monoclonal antibodies raised against LRP, both Alexis, Biochemicals, San Diego, CA); rabbit polyclonal IgGs raised against rat Yp-subunit of GSTp (Biotrin International, Dublin, Eire). Pretreatment and staining of tissue was described (14).
Primary antibodies, diluted in BSA-TBS (2.5% BSA in 0.05M Tris, 0.3M NaCl, pH 7.6) (LRP-56 and LMR5: 1:10; Yp: 1:5000), were applied overnight at 4°C. Secondary antibodies, diluted in BSA-TBS (biotinylated goat-anti-mouse IgG 1:200; biotinylated rabbit-anti-rat IgG 1:300; biotinylated goat-anti-rabbit 1:600; all from Dakopatts, Glostrup, Denmark) were used for 90 min at RT. Incubation with peroxidase-labeled streptavidin (1:300 in TBS, 45 min RT, Dakopatts) and diaminobenzidine (Sigma) was used for color development. The specificity of immunohistochemistry was confirmed by omitting the primary antibodies.
Quantitative evaluation of GSTp-positive foci.
Preneoplastic rat liver foci were first identified in the GSTp-stained serial section and were then evaluated in the LRP-stained serial section (see below) using two microscopes linked by a bridge for over-projection (Zeiss, Germany). Wherever indicated we also determined the number of The cytoplasm of 30 randomly chosen hepatocytes within the tumor and within the surrounding was measured. For each of the 60 measurements the sum of ODs of all pixels was normalized to the area evaluated. The ratio between data of the tumor and of the surrounding was calculated. For details see (27, 28) .
Statistics.
The significance of differences of means was calculated by Kruskal-Wallis-or the Wilcoxon-test.
Results
LRP expression in non-tumorous liver of humans and rats.
In immunostained sections of human and rat liver LRP was found exclusively in the cytoplasm of hepatocytes and bile epithelia, corresponding to the location of LRP in the cytoplasmic vesicle fraction (Fig. 1A -1C) . The staining intensity was most prominent in the perivenous zone of the liver lobule and decreased towards periportal zone (Fig. 1A) . Occasionally, single hepatocytes with strong LRP expression were scattered throughout the lobule (Fig. 1B) . Immunostaining with two different antibodies against LRP gave identical results as demonstrated in case of rat liver carcinoma (Fig.1, H and I ).
LRP immunostaining was confirmed by immunoblot analyses of cell-extracts obtained from 15 non-malignant human liver samples (Fig.2) . A single band of about 100kDa was detectable, which agrees with the molecular size of human LRP. Extracts derived from GLC-4 and GLC-4/ADR cells were used as negative and positive controls, respectively. 13/15 livers expressed considerable amounts of LRP. Generally, distinct interindividual variations in LRP expression were evident. Among the 2 almost negative cases one suffered from alcoholic liver disease (Fig.2, lane   1) , the other from primary biliary cirrhosis due to Byler disease (lane 15). The highest LRP expression was found in a non-cirrhotic, non-malignant liver tissue derived from a patient suffering from cholangiocellular carcinoma (lane 13).
Expression of LRP-mRNA in human hepatoma cell lines.
By RT-PCR mRNA of LRP was detectable in all human hepatoma cells tested showing marginal differences between the cell lines (Fig. 3A) . Also, LRP protein was present in all cell lines.
The protein concentration was highest in CCL-13 cells and lowest in Hep-G2 cells (Fig. 3B) .
Expression of LRP in human benign and malignant hepatocellular tumors.
All cases of benign and malignant hepatocellular tumors studied displayed a positive immunoreaction for LRP in pre(malignant) cells. Like in normal liver, LRP was found exclusively in the cytoplasm (Fig.1E-I ). LRP-stained tissue sections were evaluated by both semiquantitative scoring and densitometry . The data obtained with the two methods correlated significantly (Fig 4; Pearson´s test: r 2 = 0.7127; p < 0.0001). In Fig.5 data from the densitometric evaluation are shown.
Generally, adenomas and grade 1 carcinomas tended to an enhanced, low grade dysplastic nodules and grade 2 carcinomas to a decreased LRP expression as compared to the surrounding. High grade dysplastic nodules and carcinomas grade 3 tended to decreased but also intensely increased immunoreactions ( Fig. 1G and Fig. 5 ). The mean expression levels of both premalignant and malignant tissues did, however, not differ significantly from the surrounding.
Expression of LRP in GSTp+ preneoplasia, hepatocellular adenoma and carcinoma of the rat.
Details on the m odel system used for studying hepatocarcinogenesis in the rat were published elsewhere (13). GSTp staining was used to detect all stages of hepatocarcinogenesis ranging from initiated single cells, multicellular foci ( Fig. 1D and E) , hepatocellular adenoma and finally to carcinoma ( Fig. 1H and I ) Similar to the human situation, LRP was expressed in all (pre)malignant stages of the rat liver analyzed. Immunostaining with two different antibodies against LRP gave identical results. As one example serial sections of a rat liver carcinoma stained with the two anti-LRP antibodies are shown ( Fig.1H and I ). Expression levels did not vary significantly between (pre)malignant lesion and the adjacent tissue (Fig. 6 ).
Discussion
The expression of LRP, the major vault protein, was studied in unaltered and (pre)malignant hepatocytes, that are known for their intrinsic and acquired chemoresistance towards a great variety of cytotoxic agents. We found considerable expression of LRP in hepatocytes and bile duct epithelia in almost all liver samples studied. Hitherto two papers reported somewhat conflicting results on the occurrence of LRP in human liver. While a low expression of LRP in hepatocytes and a higher one in bile epithelia was reported (17) , others failed to detect LRP in the liver (39) . Vaults have been originally discovered in extracts from rat liver (20) . However, primary cultures of human hepatocytes that were treated with the hepatomitogens epidermal growth factor or hepatocyte growth factor stably expressed significant amounts of LRP mRNA. At the protein level LRPexpression even tended to increase within 33 days of culture (34) . These data together suggest an inherent and pronounced expression of vaults in human hepatocytes, which may relate to the specific function of this organ for activation, metabolism and excretion of xenobiotics and endogenous toxins.
In human and rat liver, we observed the highest LRP-expression in hepatocytes in the perivenous zone of the liver acinus. This contrasts to the intrahepatic distribution of P-glycoprotein being highest in the periportal and lowest in the perivenous zone and suggests different functions of these two protection proteins in normal liver (38) . Periportal and perivenous hepatocytes differ in their biochemical capacity reflecting different functions in normal liver physiology. Metabolic activities like utilization of glucose and amino acids as well as the synthesis of urea, cholesterol and bile localize preferentially to the periportal area, whereas synthesis of glycogen, fatty acids and glutamine, and xenobiotic metabolism predominate in the perivenous area (18) . Thus, vaults may fulfill a defined physiological function in the liver mainly executed by the hepatocytes within the perivenous area.
A distinct inter-individual heterogeneity in the LRP level in liver tissues was detectable. This may be due to an inherent, genetically determined LRP expression pattern, as shown for many genes involved in chemoresistance and metabolism of xenobiotics, and which often underlies the different interindividual sensitivities of humans against carcinogens and toxins (29). On the other side, many of the metabolic functions of the liver may be readily induced, e.g. upon functional load drug metabolism increases its capacity dramatically (40) . Likewise, LRP expression in lung tumor celllines (3) and 1/3 human hepatoblastoma xenocrafts (1) was upregulated upon exposure to cytotoxic drugs and to benzo[a]pyrene, a genotoxic carcinogen occurring in tobacco smoke and smoked food products (6) . Accordingly, the heterogeneity observed in our mainly cirrhotic, non-malignant liver samples may also be based on exogeneous or endogeneous toxins, such as ethanol or accumulation of inflammatory intermediates. It, however, appears to be independent of cirrhosis, since the two samples almost lacking LRP were also derived from patients suffering from cirrhosis due to ethanol abuse and Byler disease, respectively. It will be interesting to investigate, whether the interindividual differences in the LRP expression level in human liver are more or less constant or are changeable by the administration of various cytotoxic and non-cytotoxic xenobiotics.
Intrinsic and acquired forms of MDR may underlie the limited success obtained by chemotherapeutic treatments against different types of malignant tumors including liver cancer (15, 33) . Accordingly, in experimental hepatocarcinogenesis MDR plays a key role for the development of tumors. Additionally to the intrinsic chemoresistance of normal hepatocytes, (pre)malignant liver cells acquire further resistance to the cytotoxic/cytocidal effects of various hepatotoxins and hepatocarcinogens, e.g. acetylaminofluorene, nitrosamines, aflatoxin-B1 (11, 37) . This resistance provides a selection advantage in a toxic environment, i.e. proliferation of normal hepatocytes is suppressed, while resistant cells in (pre)neoplasia multiply. As a result, tumor promotion and finally malignant progression may be accelerated. The biochemical basis for this phenomenon is an increase of metabolic pathways favoring inactivation and extrusion of toxic compounds, e.g.
conjugation reactions by the GSTp and other GSH-transferases, or membrane transport by P-glycoprotein and MRP-family members (5, 8, 10, 11, 19, 31, 32, 37) . Also in humans resistance to cytotoxins seems to be important for hepatocarcinogenesis. These toxins may stem from exogenous In conclusion, our data derived from human and rat tissues demonstrate that LRP is expressed in normal and (pre)malignant hepatocytes. This suggests a possible function of LRP in the basal chemoprotection of benign and malignant liver tissue.
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